Imperial College London
Ms Emanuela Falaschetti

MsEmanuelaFalaschetti

Faculty of Medicine, School of Public Health

Deputy Head of Statistics
 
 
 
//

Contact

 

+44 (0)20 7594 1846e.falaschetti

 
 
//

Location

 

Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kiru:2016:10.3310/hta20590,
author = {Kiru, G and Bicknell, C and Falaschetti, E and Powell, J and Poulter, N},
doi = {10.3310/hta20590},
journal = {Health Technology Assessment},
title = {An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK)},
url = {http://dx.doi.org/10.3310/hta20590},
volume = {20},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Although data are inconsistent, angiotensin-converting enzyme inhibitors (ACE-Is) have been associated with a reduced incidence of abdominal aortic aneurysm (AAA) rupture in analysis of administrative databases. OBJECTIVES: (1) To investigate whether or not the ACE-I perindopril (Coversyl arginine, Servier) reduces small AAA growth rate and (2) to evaluate blood pressure (BP)-independent effects of perindopril on small AAA growth and to compare the repeatability of measurement of internal and external aneurysm diameters. DESIGN: A three-arm, multicentre, single-blind, randomised placebo-controlled trial. SETTING: Fourteen hospitals in England. PARTICIPANTS: Men or women aged ≥ 55 years with an AAA of 3.0-5.4 cm in diameter by internal or external measurement according to ultrasonography and who met the trial eligibility criteria. INTERVENTIONS: Patients were randomised to receive 10 mg of perindopril arginine daily, 5 mg of the calcium channel blocker amlodipine daily or placebo daily. MAIN OUTCOME MEASURES: The primary outcome was AAA diameter growth using external measurements in the longitudinal plane, which in-trial studies suggested was the preferred measure. Secondary outcome measures included AAA rupture, AAA repair, modelling of the time taken for the AAA to reach the threshold for intervention (5.5 cm) or referral for surgery, tolerance of study medication (measured by compliance, adverse events and quality of life) and a comparison of the repeatability of measures of internal and external AAA diameter. Patients were followed up every 3-6 months over 2 years. RESULTS: In total, 227 patients were recruited and randomised into the three groups, which were generally well matched at baseline. Multilevel modelling was used to determine the maximum likelihood estimates for AAA diameter growth. No significant differences in the estimates of annual growth were apparent [1.68 (standard error 0.02) mm, 1.77 (0.
AU  - Kiru,G
AU  - Bicknell,C
AU  - Falaschetti,E
AU  - Powell,J
AU  - Poulter,N
DO  - 10.3310/hta20590
PY  - 2016///
SN  - 1366-5278
TI  - An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK)
T2  - Health Technology Assessment
UR  - http://dx.doi.org/10.3310/hta20590
UR  - http://hdl.handle.net/10044/1/39063
VL  - 20
ER  -
Download